SEARCH

SEARCH BY CITATION

References

  • Alen F., Moreno-Sanz G., Isabel de Tena A., Brooks R. D., Lopez-Jimenez A., Navarro M. and Lopez-Moreno J. A. (2008) Pharmacological activation of CB1 and D2 receptors in rats: predominant role of CB1 in the increase of alcohol relapse. Eur. J. Neurosci. 27, 32923298.
  • Andersson M., Usiello A., Borgkvist A. et al. (2005) Cannabinoid action depends on phosphorylation of dopamine- and cAMP-regulated phosphoprotein of 32 kDa at the protein kinase A site in striatal projection neurons. J. Neurosci. 25, 84328438.
  • Barrero F. J., Ampuero I., Morales B., Vives F. and de Dios Luna Del Castillo, J., Hoenicka, J. and Garcia Yebenes, J. (2005) Depression in Parkinson's disease is related to a genetic polymorphism of the cannabinoid receptor gene (CNR1). Pharmacogenomics J. 5, 135141.
  • Blume L. C., Bass C. E., Childers S. R., Dalton G. D., Roberts D. C., Richardson J. M., Xiao R., Selley D. E. and Howlett A. C. (2013) Striatal CB1 and D2 receptors regulate expression of each other, CRIP1A and delta opioid systems. J. Neurochem. 124, 808820.
  • Borner C., Bedini A., Hollt V. and Kraus J. (2008) Analysis of promoter regions regulating basal and interleukin-4-inducible expression of the human CB1 receptor gene in T lymphocytes. Mol. Pharmacol. 73, 10131019.
  • Carriba P., Ortiz O., Patkar K. et al. (2007) Striatal adenosine A2A and cannabinoid CB1 receptors form functional heteromeric complexes that mediate the motor effects of cannabinoids. Neuropsychopharmacology 32, 22492259.
  • Centonze D., Battista N., Rossi S., Mercuri N. B., Finazzi-Agro A., Bernardi G., Calabresi P. and Maccarrone M. (2004) A critical interaction between dopamine D2 receptors and endocannabinoids mediates the effects of cocaine on striatal gabaergic Transmission. Neuropsychopharmacology 29, 14881497.
  • Chen J., Nye H. E., Kelz M. B., Hiroi N., Nakabeppu Y., Hope B. T. and Nestler E. J. (1995) Regulation of delta FosB and FosB-like proteins by electroconvulsive seizure and cocaine treatments. Mol. Pharmacol. 48, 880889.
  • Chen J. C., Su H. J., Huang L. I. and Hsieh M. M. (1999) Reductions in binding and functions of D2 dopamine receptors in the rat ventral striatum during amphetamine sensitization. Life Sci. 64, 343354.
  • Chen J. C., Chen P. C. and Chiang Y. C. (2009) Molecular mechanisms of psychostimulant addiction. Chang Gung Med. J. 32, 148154.
  • Chen H. T., Ruan N. Y., Chen J. C. and Lin T. Y. (2012) Dopamine D2 receptor-mediated Akt/PKB signaling: initiation by D2S receptor and role in quinpirole-induced behavioral activation. ASN Neuro 4, 371382.
  • Chiang Y. C. and Chen J. C. (2007) The role of the cannabinoid type 1 receptor and down-stream cAMP/DARPP-32 signal in the nucleus accumbens of methamphetamine-sensitized rats. J. Neurochem. 103, 25052517.
  • Chiu C. Q., Puente N., Grandes P. and Castillo P. E. (2010) Dopaminergic modulation of endocannabinoid-mediated plasticity at GABAergic synapses in the prefrontal cortex. J. Neurosci. 30, 72367248.
  • Galve-Roperh I., Sanchez C., Cortes M. L., Gomez del Pulgar T., Izquierdo M. and Guzman M. (2000) Anti-tumoral action of cannabinoids: involvement of sustained ceramide accumulation and extracellular signal-regulated kinase activation. Nat. Med. 6, 313319.
  • Galve-Roperh I., Rueda D., Gomez del Pulgar T., Velasco G. and Guzman M. (2002) Mechanism of extracellular signal-regulated kinase activation by the CB(1) cannabinoid receptor. Mol. Pharmacol. 62, 13851392.
  • Girault J. A., Valjent E., Caboche J. and Herve D. (2007) ERK2: a logical AND gate critical for drug-induced plasticity? Curr. Opin. Pharmacol. 7, 7785.
  • Giuffrida A., Parsons L. H., Kerr T. M., Rodriguez de Fonseca F., Navarro M. and Piomelli D. (1999) Dopamine activation of endogenous cannabinoid signaling in dorsal striatum. Nat. Neurosci. 2, 358363.
  • Glass M. and Felder C. C. (1997) Concurrent stimulation of cannabinoid CB1 and dopamine D2 receptors augments cAMP accumulation in striatal neurons: evidence for a Gs linkage to the CB1 receptor. J. Neurosci. 17, 53275333.
  • Glass M., van Dellen A., Blakemore C., Hannan A. J. and Faull R. L. (2004) Delayed onset of Huntington's disease in mice in an enriched environment correlates with delayed loss of cannabinoid CB1 receptors. Neuroscience 123, 207212.
  • Grobben B., De Deyn P. P. and Slegers H. (2002) Rat C6 glioma as experimental model system for the study of glioblastoma growth and invasion. Cell Tissue Res. 310, 257270.
  • Herkenham M., Lynn A. B., Little M. D., Johnson M. R., Melvin L. S., de Costa B. R. and Rice K. C. (1990) Cannabinoid receptor localization in brain. Proc. Natl Acad. Sci. USA 87, 19321936.
  • Herkenham M., Lynn A. B., Johnson M. R., Melvin L. S., de Costa B. R. and Rice K. C. (1991) Characterization and localization of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic study. J. Neurosci. 11, 563583.
  • Hermann H., Marsicano G. and Lutz B. (2002) Coexpression of the cannabinoid receptor type 1 with dopamine and serotonin receptors in distinct neuronal subpopulations of the adult mouse forebrain. Neuroscience 109, 451460.
  • Howlett A. C., Blume L. C. and Dalton G. D. (2010) CB(1) cannabinoid receptors and their associated proteins. Curr. Med. Chem. 17, 13821393.
  • Hwang C. K., D'Souza U. M., Eisch A. J. et al. (2001) Dopamine receptor regulating factor, DRRF: a zinc finger transcription factor. Proc. Natl Acad. Sci. USA 98, 75587563.
  • Jarrahian A., Watts V. J. and Barker E. L. (2004) D2 dopamine receptors modulate Galpha-subunit coupling of the CB1 cannabinoid receptor. J. Pharmacol. Exp. Ther. 308, 880886.
  • Kearn C. S., Blake-Palmer K., Daniel E., Mackie K. and Glass M. (2005) Concurrent stimulation of cannabinoid CB1 and dopamine D2 receptors enhances heterodimer formation: a mechanism for receptor cross-talk? Mol. Pharmacol. 67, 16971704.
  • Kim S. J., Kim M. Y., Lee E. J., Ahn Y. S. and Baik J. H. (2004) Distinct regulation of internalization and mitogen-activated protein kinase activation by two isoforms of the dopamine D2 receptor. Mol. Endocrinol. 18, 640652.
  • Kofalvi A., Rodrigues R. J., Ledent C., Mackie K., Vizi E. S., Cunha R. A. and Sperlagh B. (2005) Involvement of cannabinoid receptors in the regulation of neurotransmitter release in the rodent striatum: a combined immunochemical and pharmacological analysis. J. Neurosci. 25, 28742884.
  • Lania L., Majello B. and De Luca P. (1997) Transcriptional regulation by the Sp family proteins. Int. J. Biochem. Cell Biol. 29, 13131323.
  • Laprairie R. B., Kelly M. E. and Denovan-Wright E. M. (2012) The dynamic nature of type 1 cannabinoid receptor (CB(1)) gene transcription. Br. J. Pharmacol. 167, 15831595.
  • Lee Y. W., Son K. W., Flora G., Hennig B., Nath A. and Toborek M. (2002) Methamphetamine activates DNA binding of specific redox-responsive transcription factors in mouse brain. J. Neurosci. Res. 70, 8289.
  • Lee B., London E. D., Poldrack R. A. et al. (2009) Striatal dopamine d2/d3 receptor availability is reduced in methamphetamine dependence and is linked to impulsivity. J. Neurosci. 29, 1473414740.
  • Liu H. C., Shen J. T., Augustin L. B., Ko J. L. and Loh H. H. (1999) Transcriptional regulation of mouse delta-opioid receptor gene. J. Biol. Chem. 274, 2361723626.
  • Luo Y., Kokkonen G. C., Wang X., Neve K. A. and Roth G. S. (1998) D2 dopamine receptors stimulate mitogenesis through pertussis toxin-sensitive G proteins and Ras-involved ERK and SAP/JNK pathways in rat C6-D2L glioma cells. J. Neurochem. 71, 980990.
  • Maccarrone M., Battista N. and Centonze D. (2007) The endocannabinoid pathway in Huntington's disease: a comparison with other neurodegenerative diseases. Prog. Neurobiol. 81, 349379.
  • Maccarrone M., Rossi S., Bari M. et al. (2008) Anandamide inhibits metabolism and physiological actions of 2-arachidonoylglycerol in the striatum. Nat. Neurosci. 11, 152159.
  • Marcellino D., Carriba P., Filip M. et al. (2008) Antagonistic cannabinoid CB1/dopamine D2 receptor interactions in striatal CB1/D2 heteromers. A combined neurochemical and behavioral analysis. Neuropharmacology 54, 815823.
  • McCaw E. A., Hu H., Gomez G. T., Hebb A. L., Kelly M. E. and Denovan-Wright E. M. (2004) Structure, expression and regulation of the cannabinoid receptor gene (CB1) in Huntington's disease transgenic mice. Eur. J. Biochem. 271, 49094920.
  • McGinty J. F., Shi X. D., Schwendt M., Saylor A. and Toda S. (2008) Regulation of psychostimulant-induced signaling and gene expression in the striatum. J. Neurochem. 104, 14401449.
  • Meschler J. P. and Howlett A. C. (2001) Signal transduction interactions between CB1 cannabinoid and dopamine receptors in the rat and monkey striatum. Neuropharmacology 40, 918926.
  • Miller L. K. and Devi L. A. (2011) The highs and lows of cannabinoid receptor expression in disease: mechanisms and their therapeutic implications. Pharmacol. Rev. 63, 461470.
  • Mukhopadhyay S., McIntosh H. H., Houston D. B. and Howlett A. C. (2000) The CB(1) cannabinoid receptor juxtamembrane C-terminal peptide confers activation to specific G proteins in brain. Mol. Pharmacol. 57, 162170.
  • Navarro G., Carriba P., Gandia J. et al. (2008) Detection of heteromers formed by cannabinoid CB1, dopamine D2, and adenosine A2A G-protein-coupled receptors by combining bimolecular fluorescence complementation and bioluminescence energy transfer. ScientificWorldJournal 8, 10881097.
  • Onaivi E. S., Leonard C. M., Ishiguro H., Zhang P. W., Lin Z., Akinshola B. E. and Uhl G. R. (2002) Endocannabinoids and cannabinoid receptor genetics. Prog. Neurobiol. 66, 307344.
  • Pan B., Hillard C. J. and Liu Q. S. (2008) D2 dopamine receptor activation facilitates endocannabinoid-mediated long-term synaptic depression of GABAergic synaptic transmission in midbrain dopamine neurons via cAMP-protein kinase A signaling. J. Neurosci. 28, 1401814030.
  • Pickel V. M., Chan J., Kearn C. S. and Mackie K. (2006) Targeting dopamine D2 and cannabinoid-1 (CB1) receptors in rat nucleus accumbens. J. Comp. Neurol. 495, 299313.
  • Przybyla J. A. and Watts V. J. (2010) Ligand-induced regulation and localization of cannabinoid CB1 and dopamine D2L receptor heterodimers. J. Pharmacol. Exp. Ther. 332, 710719.
  • Rezayof A., Habibi P. and Zarrindast M. R. (2011) Involvement of dopaminergic and glutamatergic systems of the basolateral amygdala in amnesia induced by the stimulation of dorsal hippocampal cannabinoid receptors. Neuroscience, 175, 118126.
  • Rinaldi-Carmona M., Barth F., Congy C. et al. (2004) SR147778 [5-(4-bromophenyl)-1-(2,4-dichlorophenyl)-4-ethyl-N-(1-piperidinyl)-1H-pyrazole-3 -carboxamide], a new potent and selective antagonist of the CB1 cannabinoid receptor: biochemical and pharmacological characterization. J. Pharmacol. Exp. Ther. 310, 905914.
  • Robbe D., Alonso G., Duchamp F., Bockaert J. and Manzoni O. J. (2001) Localization and mechanisms of action of cannabinoid receptors at the glutamatergic synapses of the mouse nucleus accumbens. J. Neurosci. 21, 109116.
  • Rylski M., Amborska R., Zybura K., Konopacki F. A., Wilczynski G. M. and Kaczmarek L. (2008) Yin Yang 1 Expression in the Adult Rodent Brain. Neurochem. Res. 12, 25562564.
  • Shi Y., Lee J. S. and Galvin K. M. (1997) Everything you have ever wanted to know about Yin Yang 1. Biochim. Biophys. Acta 1332, F49F66.
  • Usiello A., Baik J. H., Rouge-Pont F., Picetti R., Dierich A., LeMeur M., Piazza P. V. and Borrelli E. (2000) Distinct functions of the two isoforms of dopamine D2 receptors. Nature 408, 199203.
  • Valjent E., Pages C., Rogard M., Besson M. J., Maldonado R. and Caboche J. (2001) Delta 9-tetrahydrocannabinol-induced MAPK/ERK and Elk-1 activation in vivo depends on dopaminergic transmission. Eur. J. Neurosci. 14, 342352.
  • Valjent E., Pascoli V., Svenningsson P. et al. (2005) Regulation of a protein phosphatase cascade allows convergent dopamine and glutamate signals to activate ERK in the striatum. Proc. Natl Acad. Sci. USA 102, 491496.
  • Vantaggiato C., Formentini I., Bondanza A., Bonini C., Naldini L. and Brambilla R. (2006) ERK1 and ERK2 mitogen-activated protein kinases affect Ras-dependent cell signaling differentially. J. Biol. 5, 14.
  • Yao L., Fan P., Jiang Z., Mailliard W. S., Gordon A. S. and Diamond I. (2003) Addicting drugs utilize a synergistic molecular mechanism in common requiring adenosine and Gi-beta gamma dimers. Proc. Natl Acad. Sci. USA 100, 1437914384.
  • Yao L., McFarland K., Fan P., Jiang Z., Ueda T. and Diamond I. (2006) Adenosine A2a blockade prevents synergy between mu-opiate and cannabinoid CB1 receptors and eliminates heroin-seeking behavior in addicted rats. Proc. Natl Acad. Sci. USA 103, 78777882.
  • Zarrindast M. R., Mahboobi S., Sadat-Shirazi M. S. and Ahmadi S. (2011) Anxiolytic-like effect induced by the cannabinoid CB1 receptor agonist, arachydonilcyclopropylamide (ACPA), in the rat amygdala is mediated through the D1 and D2 dopaminergic systems. J. Psychopharmacol. 25, 131140.
  • Zhang P. W., Ishiguro H., Ohtsuki T., Hess J., Carillo F., Walther D., Onaivi E. S., Arinami T. and Uhl G. R. (2004) Human cannabinoid receptor 1: 5′ exons, candidate regulatory regions, polymorphisms, haplotypes and association with polysubstance abuse. Mol. Psychiatry 9, 916931.